Injecto Polymers IPO Day 5: GMP ₹0
Welcome back to our daily deep dive into the Injecto Polymers SME IPO on the BSE. Today marks the fifth and final day of subscription, and we’re here to break down the numbers and give you the latest on the Grey Market Premium (GMP). It’s been a quiet journey so far, and as we enter the closing hours, investors are making their final decisions. Let’s see where Injecto Polymers stands.
Subscription Status
As of Day 5, the subscription numbers for Injecto Polymers remain at zero across all categories: Retail, Non-Institutional Investors (NII), and Qualified Institutional Buyers (QIB). This is a significant point to consider. Typically, by the final day, we’d expect to see some level of interest, even if it’s modest. The lack of subscriptions could indicate a few things. It might mean investors are waiting until the very last moment, which is not uncommon for SME IPOs. However, it could also suggest a lack of immediate enthusiasm or perhaps a wait-and-watch approach from institutional players. For retail investors, this zero subscription across the board offers a clean slate, but it also means there’s no strong market signal of demand just yet. The lot size of 1200 shares at an issue price of ₹100 means each retail lot is valued at ₹1,20,000. The absence of any bids is certainly noteworthy and something to keep a close eye on as the subscription window officially closes.
| Category | Subscription | Progress |
|---|---|---|
| Retail | 0.00x | |
| NII / HNI | 0.00x | |
| QIB | 1.57x | |
| Total | 1.57x |
GMP Update
Now, let’s talk about the Grey Market Premium (GMP). The current GMP for Injecto Polymers is ₹0. Yesterday, it was also ₹0. This unchanged status means the market sentiment, as reflected by the unofficial premium, hasn’t shifted. A GMP of ₹0 suggests that the market is currently expecting the stock to list at its issue price of ₹100. There’s no additional premium being factored in by the grey market operators. While a neutral GMP isn’t necessarily a bad sign, it doesn’t offer any immediate upside potential post-listing based on this indicator alone. The expectation of listing at the issue price is the baseline scenario here.
Should You Apply?
So, the big question: should you be applying for Injecto Polymers? The subscription data is, to put it mildly, uninspiring at this point. Zero subscriptions across all categories on the final day is unusual and doesn’t paint a picture of overwhelming demand. Coupled with a GMP of ₹0, which indicates an expected listing at par, the immediate post-listing gains aren’t screaming for attention. However, it’s important to remember that SME IPOs can sometimes see a surge in last-minute applications, especially if there’s a perceived undervaluation or strong fundamentals that aren’t immediately reflected in subscription numbers. The IPO period is from 2026-09-11 to 2026-09-16, so there are still a few hours left to see if any last-minute rush materializes. If you’re considering an investment, it’s crucial to do your own due diligence on Injecto Polymers’ business model, financials, and future prospects. Remember, as SEBI advisors often remind us, investing in the stock market carries risks, and it’s always wise to invest within your risk appetite. The lack of current demand and a neutral GMP means you’re primarily betting on the company’s long-term potential rather than an immediate listing gain.